A Toxin against Pain
For years, scientists have promised a new wave of drugs derived from sea life. A recently approved analgesic that is a synthetic version of a snail toxin has become one of the first marine pharmaceuticals
By Gary Stix
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
The past 18 months were very good ones for hypnotists, yoga teachers and acupuncturists. For many chronic pain sufferers, promises of relief from various forms of alternative medicine seemed like rational options amid the unending stream of negative reports about Vioxx, Celebrex, Aleve and Rush Limbaugh's addiction to painkillers.
Not all was lost for patients who prefer medicine to meditation. With little fanfare, the Food and Drug Administration approved in late December two new drugs intended to treat a form of pain that often proves resistant to anti-inflammatories and opiates--the two predominant classes of pharmaceuticals for analgesia. Medical specialists welcomed their arrival. "It's an embarrassment that we're treating pain with opiates and aspirinlike compounds," notes Edwin McCleskey of the Oregon Health and Sciences University. "Opiates are more than 2,000 years old, and aspirin is nearly 200 years old."
Subscribe to Support Independent Journalism
Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.
When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.
Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber
